UNSPSC 51372208: Dextropropoxyphene hydrochloride

This classification denotes an opioid receptor agonist and opioid with the molecular formula C22H29NO2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier CB2TL9PS0T, chemically known as 2-butanol, 4-(dimethylamino)-3-methyl-1,2-diphenyl-, propionate (ester), hydrochloride, (+)- but more generally known as dextropropoxyphene hydrochloride, which bears US NIH Compound Identifier 15424.

European Medicines Agency schedules Dextropropoxyphene hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01649MIG. Most nations, for tariff and trade purposes, schedule dextropropoxyphene hydrochloride under HS 29221400. SMILES: CCC(=O)O[C@](CC1CCCCC1)(C2CCCCC2)[C@H](C)CN(C)C.CL.

UNSPSC 51372208 Dextropropoxyphene hydrochloride is a Commodity code that frames pharmaceutical products for state and local health and human services procurement, though recent state and local solicitations under this code show little direct purchasing of dextropropoxyphene itself and instead reflect broader pharmaceutical supply contracting. State and local health departments, counties, and cooperative purchasing alliances are the primary issuing bodies, with activity spanning county health initiatives, state pharmacy benefit programs, and multistate cooperative purchasing vehicles. The work solicited includes procurement of generic pharmaceuticals and over-the-counter products through authorized wholesaler networks, direct-to-manufacturer prescription programs, and emergency response medical supplies such as naloxone.

Seminole County, Florida; the Texas Health and Human Services Commission; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) represent the most recent activity. Seminole County issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a response deadline of July 26, 2023. Texas HHS posted RFI HHS0017013 on April 3, 2026 to gather market intelligence on direct-to-manufacturer prescription programs as a precursor to formal procurement. MMCAP, administered by the Minnesota Department of Administration, issued RFP S1070000015802 in January 2026 with a March 26, 2026 response deadline to establish multiple contracts for generic pharmaceuticals and OTC products distributed across participating state and local facilities in Minnesota and Oregon, requiring compliance with cGMP and Drug Supply Chain Security Act standards, $5 million commercial general liability insurance, and a 3 percent administrative fee on all purchases.